Gold Nanoparticle-Based Drug Delivery Platform for Antineoplastic Chemotherapy
Gold nanoparticles (AuNPs) have demonstrated increasingly wide applications in drug delivery due to their unique physicochemical and optical properties as well as low toxicity. Compared to the organic nanocarriers for therapeutic agents, AuNPs have shown superior performance as drug delivery vectors, including the inert nature, well-developed synthesis strategies, tunable size, and flexible and easy surface modification with various chemical and biological molecules. In this review, we emphasize on the applications of AuNPs in the aspect of improving pharmaceutical property and therapeutic efficacy of drugs, especially those covalently and noncovalently connected to the surface of AuNPs. Acting as a solid core to link drugs and their derivatives, AuNPs provide the nano-prodrug system with compressed size, high loading efficiency, three-dimension structure, and enhanced cellular uptake capability. With the intensive and systematical investigation of the drug-connected AuNPs, several important issues will become the hot but emergent topics for future research in this field, such as the toxicity in live human subjects, ultimate destination, and possible pathways and mechanisms for their absorption, circulation, distribution, metabolism, and excretion.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: July 1, 2014
More about this publication?
- Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites